IP Group (LSE: IPO) rejects Railpen proposal worth up to 82.6p as valuation clash deepens

IP Group plc (LSE: IPO) has rejected a revised takeover proposal from Railways Pension Trustee Company Limited that combines 61 pence in cash, a distribution of IP Group’s Oxford Nanopore Technologies plc holding valued at 10.3 pence per share and a contingent value right worth up to 11.3 pence. The immediately observable value was approximately 71.3 pence per share, while the maximum theoretical consideration could reach 82.6 pence only if the value linked to IP Group’s former Metsera interests rises substantially before the end of 2029. The IP Group board unanimously concluded that the proposal continued to undervalue its portfolio, origination platform and long-term prospects, but requested a seven-day extension to permit further negotiations. Railpen now has until 5:00 p.m. London time on July 27, 2026, to announce a firm offer or withdraw. The central argument is no longer simply about the size of the cash payment, but about whether current shareholders or a pension-backed consortium should capture the uncertain future value of Oxford Nanopore Technologies, Pfizer’s obesity portfolio and IP Group’s wider science investments.

Why did IP Group reject Railpen’s proposal despite a potential value of 82.6 pence?

The headline value requires careful qualification. IP Group shareholders would receive 61 pence in cash and a pro rata share of the company’s entire Oxford Nanopore Technologies holding, valued at 10.3 pence per IP Group share using the Oxford Nanopore Technologies closing price on July 17. Those two components created an implied value of 71.3 pence, before attaching any value to the contingent right linked to Metsera.

The remaining 11.3 pence is neither guaranteed nor payable when the transaction completes. It would depend on the value of IP Group’s Metsera-related economic interest increasing above a compounded hurdle by December 31, 2029, or reaching the relevant threshold earlier through a disposal. The contingent right would reach its maximum only if that interest were valued at approximately £500 million.

IP Group’s last reported net asset value was 110.4 pence per share. The 71.3 pence observable proposal value therefore represented a discount of approximately 35.4% to net asset value. Even including the full 11.3 pence contingent payment, which may never become payable, the theoretical maximum of 82.6 pence would remain approximately 25.2% below the last reported net asset value. IP Group’s resistance is therefore grounded in the size of the discount as well as the uncertainty of the payment structure.

Railpen could counter that investment-company net asset values are not automatically realisable in cash. IP Group has historically traded at a substantial discount because investors apply reductions for portfolio uncertainty, operating costs, limited liquidity and the long time required to convert early-stage science into exits. A buyer does not normally pay full accounting value for every private asset when some investments may require years of additional funding.

However, IP Group’s board is being asked to transfer control of a platform that ended 2025 with a £908.1 million portfolio and £211 million of gross cash and deposits. The company also reported £68.1 million of cash proceeds during the year and completed a £75 million share buyback that retired 9% of its share capital. Those figures support the argument that the portfolio contains monetisable assets rather than merely optimistic laboratory valuations.

How much of Railpen’s IP Group proposal would shareholders receive with reasonable certainty?

The 61 pence cash component is the clearest part of the proposal, although even that remains conditional because Railpen has not announced a firm intention to make an offer. The Oxford Nanopore Technologies component would fluctuate with the sequencing company’s market price until the transaction structure and distribution mechanism were fixed.

Oxford Nanopore Technologies shares were valued at 10.6 pence per IP Group share when Railpen described the proposal on July 17. By the time IP Group issued its response using the July 17 closing market value, the contribution had fallen to 10.3 pence. That relatively small movement illustrates why the 71.3 pence figure is an equity-linked reference value rather than a fixed cash price.

Shareholders would also need to consider the practical consequences of receiving Oxford Nanopore Technologies shares. Some investors may welcome direct exposure to a listed sequencing company with strong revenue growth and a stated path toward adjusted earnings before interest, tax, depreciation and amortisation breakeven in 2027. Others may prefer IP Group to manage the holding, determine the timing of any sale and return capital through its established buyback or distribution process. Oxford Nanopore Technologies reported 2025 revenue of £223.9 million, up 24.2% at constant currency, and ended the year with £302.8 million of cash and liquid investments.

The contingent value right is the least certain component. IP Group shareholders would receive only 30% of value created above a hurdle that compounds the £128.2 million Metsera reference value at 10% annually. Railpen’s consortium would retain 70% of the incremental upside above that threshold, in addition to acquiring the remainder of IP Group’s portfolio and investment platform.

That structure explains why the IP Group board may view the 82.6 pence maximum as visually attractive but economically incomplete. The contingent right asks existing shareholders to bear the risk that the Metsera-linked value does not grow sufficiently, while surrendering most of the upside if Pfizer’s programmes perform exceptionally well.

Why is the Metsera contingent value right the most controversial part of Railpen’s approach?

IP Group’s exposure does not primarily arise from continuing ownership of Metsera as an independent company. Pfizer completed its acquisition of Metsera in November 2025, bringing a portfolio of clinical-stage obesity and cardiometabolic programmes into Pfizer’s internal medicine pipeline. IP Group retains financial exposure through intellectual-property licences, potential milestone payments and royalties associated with several of those programmes.

At December 31, 2025, IP Group valued the discounted future royalty and milestone income connected with those rights at £128.2 million. That valuation was a major contributor to the 13% increase in net asset value per share to 110.4 pence. IP Group’s exposure includes Pfizer’s PF’3944 programme alongside PF’3945, PF’4696 and PF’6795.

The commercial opportunity is potentially significant but remains highly uncertain. Pfizer reported Phase 2b results in June supporting monthly dosing for berobenatide, previously identified as PF’3944, and outlined plans to advance ten Phase 3 studies during 2026 across weight management and obesity-related conditions. Those trials improve visibility but do not remove clinical, regulatory, manufacturing or competitive risk.

Railpen’s hurdle requires the £128.2 million reference value to rise to approximately £170.6 million by the end of 2029 before shareholders begin sharing in additional gains. Only 30% of the value above that level would flow through the contingent right, and the payment would be capped at 11.3 pence per IP Group share.

The structure therefore protects the proposed consortium against paying upfront for a pharmaceutical outcome that may not occur. That is commercially rational for a buyer. It is less attractive for IP Group shareholders because the existing company already owns the exposure and could retain the entire benefit, subject to its obligations to Imperial College London and other contractual arrangements, if the programmes eventually generate major milestones or royalties.

This is the heart of the valuation dispute. Railpen is effectively saying that uncertain drug-development upside should be shared only after a meaningful return threshold. IP Group is arguing that shareholders should not surrender 70% of the incremental value simply because the public market currently discounts the portfolio.

Why does Railpen want to combine IP Group with a consortium of United Kingdom pension funds?

Railpen has been an IP Group shareholder since 2019 and held approximately 18.4% of the company when it announced the improved proposal. It intends to reinvest its existing stake rather than cashing out and has been attempting to assemble a consortium of other United Kingdom pension funds to support the transaction.

The strategic logic is broader than a conventional financial takeover. IP Group has relationships with universities, research institutions, scientists and early-stage companies across health technology, deep technology and clean technology. Railpen believes that placing the platform under long-term pension ownership could create a larger investment manager capable of supplying patient capital from scientific formation through commercial scale.

That ambition aligns with government efforts to increase pension investment in private markets and British growth companies. The Mansion House Accord involves major pension providers targeting 10% of default-fund assets in private markets by 2030, including 5% in United Kingdom investments. Government estimates have suggested that successful implementation could unlock approximately £50 billion of additional private-market capital, with more than £25 billion directed toward the United Kingdom.

IP Group is an obvious platform through which pension funds could pursue those objectives. It already originates university-linked investments, manages third-party capital through Parkwalk Advisors and has entered a relationship with Aberdeen to manage a portfolio of early-stage and growth investments. At the end of 2025, third-party assets under management were £557 million.

The potential contradiction is that a transaction presented as supporting British innovation may require buying out existing public shareholders at a deep discount to reported net asset value. Pension capital is expected to be patient, but it is not charitable. Railpen must demonstrate that the acquisition benefits its scheme members, which means securing attractive economics rather than simply validating IP Group’s accounting valuation.

That creates an unusual negotiation. Both parties support greater pension participation in British science, but they disagree over who should fund the transition and who should retain the resulting upside.

Does IP Group’s persistent share-price discount justify Railpen’s lower valuation?

IP Group shares closed at 66.2 pence on July 20, up 2.48% for the session. The board’s rejection was released after the London market had closed, so the price did not yet reflect the company’s decision to seek a higher proposal.

The July 20 close placed the shares about 7.7% below the 71.3 pence value represented by cash and Oxford Nanopore Technologies shares. It was approximately 19.9% below the theoretical maximum consideration of 82.6 pence and around 40% below IP Group’s last reported net asset value of 110.4 pence.

IP Group shares gained approximately 3.1% between July 15 and July 20 and around 2.3% over the month from June 19. The stock remained within a 52-week range of 48 pence to 72 pence, meaning the takeover speculation had moved the shares toward the upper end of their annual range without persuading investors to price in a firm or significantly improved offer.

The discount is partly structural. Venture and intellectual-property investment companies often trade below stated net asset value because private holdings are difficult to value, future funding needs can dilute returns and exits arrive irregularly. IP Group’s own 2024 results demonstrated this volatility when net asset value per share fell 15%, partly because of reductions involving Oxford Nanopore Technologies, First Light Fusion and Istesso.

The 2025 improvement showed the opposite side of that model. Pfizer’s acquisition of Metsera, the Hinge Health flotation and other exits increased visibility and supported net asset value growth. Portfolio companies raised £914 million during the year, while IP Group invested £70.5 million across 31 businesses.

Railpen’s proposal attempts to monetise the market discount by offering shareholders a premium to the traded price while acquiring the portfolio below reported value. That approach is normal takeover arithmetic. The board’s job is to determine whether the market discount represents permanent friction or temporary mispricing that shareholders should not be forced to crystallise.

Can IP Group’s standalone strategy deliver more value than Railpen’s revised proposal?

IP Group has committed to producing more than £250 million of exits between the start of 2025 and the end of 2027. It generated £68.1 million during 2025 and subsequently completed the sale of its remaining Hinge Health holding, producing a further £16.8 million in early 2026.

The company’s £211 million gross cash position at the end of 2025 provides flexibility to support selected portfolio companies, repurchase undervalued shares and withstand delays in private-market exits. A further £30 million had also been accumulated for future shareholder returns after the reporting period.

The strongest standalone argument is that shareholders already own the assets Railpen wants to acquire. If Oxford Nanopore Technologies continues growing, Pfizer’s obesity programmes progress and other portfolio businesses reach liquidity events, IP Group could close part of the valuation discount without surrendering control.

The weakness is timing. Scientific investments can consume capital for years, and even technically successful businesses may struggle to achieve profitable commercial scale. Public shareholders have repeatedly shown limited patience with long-duration portfolios, particularly when management fees and corporate costs continue while asset realisations remain unpredictable.

IP Group must therefore demonstrate that its model can convert scientific progress into recurring shareholder returns. Buybacks reduce the share count and can be highly accretive when executed below net asset value, but they do not by themselves prove that the underlying assets can be sold at their recorded values.

Rejecting Railpen’s proposal raises the performance benchmark. The board must now show why 71.3 pence of observable value and a potential 11.3 pence contingent payment are insufficient, not simply by citing net asset value, but by delivering exits, narrowing the discount and returning capital.

What must Railpen improve before the July 27 takeover deadline?

The simplest route would be a higher cash payment. Raising the guaranteed component would reduce shareholders’ dependence on Oxford Nanopore Technologies market movements and the uncertain Metsera contingent right. Even a moderate cash increase could materially change the balance between immediate certainty and long-term optionality.

Railpen could also improve the Metsera structure. A lower hurdle, a higher shareholder participation rate or a larger cap would allow investors to retain more of the potential upside while protecting the consortium from paying full value before clinical milestones are achieved.

Deliverability is equally important. Railpen’s proposal remains conditional on forming a consortium, completing confirmatory due diligence and securing the unanimous recommendation of the IP Group board. Until the consortium is identified and funding commitments are clear, shareholders cannot treat the proposal as equivalent to a fully financed firm offer.

The Oxford Nanopore Technologies distribution mechanism also requires clarification. Shareholders need to know how shares would be allocated, whether taxes or transaction costs would reduce value, how fractional entitlements would be handled and whether there would be restrictions on immediate disposal.

IP Group has signalled that it is willing to engage rather than closing the process. Requesting the seven-day extension indicates that the board believes a recommendable proposal may still be possible. It also increases pressure on Railpen to show its best terms rather than relying on the public market’s existing discount.

Railpen must announce a firm intention to make an offer or withdraw by July 27 unless the deadline is extended again with Takeover Panel approval. A withdrawal could push IP Group shares lower, while a materially higher proposal would test whether the board’s valuation objections are genuinely financial or partly strategic.

What does the IP Group takeover contest mean for British science and pension investment?

The transaction is a test case for the government’s ambition to connect domestic pension savings with British innovation. IP Group owns a ready-made science-investment platform, while Railpen supplies long-duration capital and institutional scale.

A successful combination could make it easier to finance companies through the difficult period between university research and commercial maturity. It could also create a platform through which additional pension schemes gain diversified exposure to private technology and healthcare assets without building their own specialist teams.

However, the takeover also highlights why this policy objective is difficult. Pension trustees must seek returns for members, public shareholders expect fair value and early-stage companies require patient funding on uncertain timelines. Those interests overlap, but they are not identical.

Paying too much would weaken the investment case for Railpen members. Paying too little would transfer value from IP Group shareholders and reinforce concerns that London’s persistent investment-company discounts allow strategic portfolios to be privatised cheaply.

The best outcome may therefore require more than a higher number. A revised structure that provides stronger cash certainty, preserves meaningful participation in the Pfizer-linked upside and demonstrates committed pension-fund backing could align the competing interests more effectively.

Key takeaways on what Railpen’s revised proposal means for IP Group shareholders

• IP Group has rejected Railpen’s revised proposal but has allowed seven more days for discussions over a potentially improved transaction.
• The proposal included 61 pence in cash and Oxford Nanopore Technologies shares worth approximately 10.3 pence per IP Group share.
• The observable consideration of 71.3 pence represented a discount of roughly 35.4% to IP Group’s last reported net asset value of 110.4 pence.
• The additional 11.3 pence is a contingent maximum rather than guaranteed consideration and depends on substantial growth in the Metsera-linked value.
• IP Group shareholders would receive only 30% of incremental Metsera value after a 10% annual hurdle, while Railpen’s consortium would retain 70%.
• Railpen held approximately 18.4% of IP Group and intends to assemble a consortium of United Kingdom pension funds to acquire the company.
• The transaction could create a scaled pension-backed investment manager focused on British science, university research and growth companies.
• IP Group’s £211 million gross cash position, exit programme and buybacks support its standalone case, but the persistent share-price discount weakens its negotiating position.
• IP Group shares closed at 66.2 pence on July 20, below the observable proposal value and about 40% below reported net asset value.
• Railpen has until July 27, 2026, to increase the proposal, announce a firm offer, seek another extension or withdraw.